Search PubMed⌕ Search

Biomedical subjects

G W Ellison

Publications and source records attributed to G W Ellison.

At least 109 records · Page 6Linked to original sources
PubMed1977

Swine influenza virus vaccination in patients with multiple sclerosis.

A double-blind, placebo-controlled study was conducted to evaluate the safety and efficacy of inactivated influenza virus vaccines in patients with multiple sclerosis. The vaccine used contained 200 chick cell-agglutinating (CCA) units of influenza A/New Jersey/76 and 200 CCA units of influenza A/Victoria/75 whole viruses (Merrell-National Laboratories, Cincinnati, Ohio). The frequency of clinical relapses of multiple sclerosis was the same in the vaccine-treated (four of 33 patients) and placebo-treated (four of 33) groups. An untreated control group had a slightly higher rate of relapses (four of 22). Toxic reactions to the vaccine were not a significant problem. The efficacy of the vaccination as measured by titers of hemagglutination-inhibiting antibody was comparable to that reported for the general population. However, patients with preexisting antibody were less responsive to the vaccine than normal controls studied previously. The patients who did not respond to the vaccine tended to be older and more disabled. There were no changes in titers of antibody to rubeola or rubella virus after vaccination or in relation to change in clinical course. It is concluded that the vaccine is safe and effective in patients with multiple sclerosis.

Antibodies, Viral↗
PubMed1975

Oligodendroglial toxicity by serum and lymphocytes from patients with multiple sclerosis.

The gliotoxic effect of multiple sclerosis serums and lymphocytes was investigated by the measurement of Cr51 release from prelabeled bovine oligodendroglia. There was no difference in glial toxicity between multiple sclerosis patients and normal controls except for a depression of Cr51 release from bovine oligodendroglia in the presence of autologous serum plus lymphocytes in the multiple sclerosis patients compared with the normal controls. This correlated with the phase of the disease and may be due to the presence of a lymphotoxic factor in the active multiple sclerosis serums.

Animals↗
PubMed1974

Studies on a murine form of spontaneous lower motor neuron degeneration--the wobbler (wa) mouse.

The wobbler (wr) mouse has been considered an animal model of spontaneous lower motor neuron degeneration which is inherited as an autosomal recessive trait. Previously available data are, however, also compatible with genetic factors playing a necessary though not exclusive role in the expression of the wobbler trait. The present report describes the results of chromosome analyses, electromyography and selected histochemical studies on wobbler mice, as well as studies exploring the possible participation of infectious agents, transneuronal effects, retrograde effects, aging, circulating toxins and immunologic factors in the pathogenesis of the wobbler disorder. The data obtained do not implicate any of these mechanisms in the pathogenesis of the wobbler trait and also indicate that the wobbler mouse is not a clinical variant of the recently described type C oncornavirus-induced murine paralytic disease.

Aging↗
PubMedDate not supplied

A parametric scale for BAEP latencies in multiple sclerosis.

A parametric scale for measuring BAEP latencies is set forth here for use in multiple sclerosis (MS) therapeutic trials and similar longitudinal studies. Derived constants are used to create a synthetic I-V interpeak interval, needed for cases where V (or other waves) are absent. Transitional peaks (peaks on the verge of disappearing) were studied in MS patients and used to determine appropriate values for the weighting constants. The resulting scale or index makes use of latencies to whichever peaks are still present. In theory such a scale is more sensitive to small changes than either a simple ordinal scale of which peaks remain or a parametric scale of I-V interpeak intervals excluding the 25-40% of MS records with absent wave V. To test this synthetic I-V index in practice, we studied it in 100 MS patients entering a therapeutic trial. It was found to correlate appropriately with patients' history, physical examination, and clinical scales at entry into the trial. Parametric statistical analysis of the derived scale was able to show a statistically significant drug effect during the therapeutic trial, whereas 3 other data analysis techniques showed at best a trend that did not quite reach significance.

Adult↗